UK NICE final guidance recommends use of Invokana (canagliflozin), Farxiga (dapagliflozin) and Jardiance (empagliflozin) in type 2 diabetes- Janssen Pharmaceuticals / AstraZeneca / Eli Lilly / Boehringer

According to final guidance from UK NICE, Invokana (canagliflozin), from Janssen Pharmaceuticals, Farxiga (dapagliflozin) from AstraZeneca, and Jardiance (empagliflozin), from Eli Lilly/Boehringher, as monotherapies are recommended as options for treating type 2 diabetes in adults for whom metformin is contraindicated or not tolerated and when diet and exercise alone do not provide adequate glycaemic control, only if a dipeptidyl peptidase-4 (DPP-4) inhibitor would otherwise be prescribed and a sulfonylurea or pioglitazone is not appropriate.

Adults whose treatment with canagliflozin, dapagliflozin or empagliflozin as monotherapy is not recommended in this NICE guidance, but was started within the NHS before this guidance was published, should be able to continue treatment until they and their NHS clinician consider it appropriate to stop.